Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 3/20 | 0.54 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.53 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.48 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA7 | P43166 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31336107 | 1.00 | CA1 (0.54) | CA1CA2HSP90AA1AKR1C4AKR1C3 | |
| SCHEMBL28335829 | 0.91 | CA1 (0.59) | CA1CA2HSP90AA1AKR1C4AKR1C3 | |
| SCHEMBL5547041 | 0.88 | CA1 (0.61) | CA1CA2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL2478971 | 0.86 | TSHR (0.56) | CA1CA2HSP90AA1AKR1C4AKR1C3 | |
| SCHEMBL30061803 | 0.86 | TSHR (0.56) | CA1CA2HSP90AA1AKR1C4AKR1C3 | |
| SCHEMBL460201 | 0.82 | CA1 (0.56) | CA1CA2ALDH1A1HPGDHSD17B10 | |
| SCHEMBL597374 | 0.81 | ALDH1A1 (0.63) | CA1CA2HSP90AA1AKR1C3AKR1C2 | |
| Ethylbenzene SCHEMBL10728167 | 0.81 | HSP90AA1 (0.59) | CA1CA2HSP90AA1ALDH1A1HPGD | |
| SCHEMBL30752462 | 0.81 | CA1 (0.57) | CA1CA2AKR1C4AKR1C3AKR1C2 | |
| SCHEMBL8279091 | 0.81 | CA1 (0.57) | CA1CA2AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4720038-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2026-04-08 | — | — | EP | disclosed |
| WO-2024246496-A1 | (HETERO)ARYL-CARBONYL-HETEROBICYCLIC COMPOUNDS AS INHIBITORS OF PMS2 FOR CANCER AND DEGENERATIVE ILLNESSES | Neophore Limited (GB) | 2024-12-05 | — | — | WO | disclosed |
| US-10889552-B2 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | ONCOZEN CO.. LTD. (KR) | 2021-01-12 | — | — | US | disclosed |
| US-10464907-B2 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-11-05 | — | — | US | disclosed |
| US-10464907-B2 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-11-05 | — | — | US | disclosed |
| US-20190031620-A1 | NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-01-31 | — | — | US | disclosed |
| US-20190031620-A1 | NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF | INDUSTRY ACADEMIC COOPERATION FOUNDATION KEIMYUNG UNIVERSITY (KR) | 2019-01-31 | — | — | US | disclosed |
| EP-2565245-B1 | Moisture-proof material | NITTO DENKO CORP (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-9914719-B2 | Hydroxybenzamide derivatives and their use as inhibitors of HSP90 | ASTEX THERAPEUTICS LTD. (GB) | 2018-03-13 | — | — | US | disclosed |
| US-20070197787-A1 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS | 2007-08-23 | — | — | US | disclosed |
| US-20070197787-A1 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS | 2007-08-23 | — | — | US | disclosed |
| US-20070197787-A1 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS | 2007-08-23 | — | — | US | disclosed |
| US-7208630-B2 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208630-B2 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS (US) | 2007-04-24 | — | — | US | disclosed |
| US-7208630-B2 | Heat shock protein 90 inhibitors | UNIVERSITY OF KANSAS (US) | 2007-04-24 | — | — | US | disclosed |
| WO-2006117669-A1 | AMIDE RESORCINOL COMPOUNDS | PFIZER INC. (US) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006109085-A1 | HYDROXYBENZAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF HSP90 | ASTEX THERAPEUTICS LIMITED (GB) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006047740-A2 | HEAT SHOCK PROTEIN 90 INHIBITORS | UNIVERSITY OF KANSAS (US) | 2006-05-04 | — | — | WO | disclosed |
| US-20060089495-A1 | Heat shock protein 90 inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10889552-B2 | Dihydroxybenzamide compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | HSP90AB1, HSP90AA1, HSP90AB2P | CA1 4543/4885CA2 3655/4885HSP90AA1 2/4885 |
| US-20060089495-A1 | Heat shock protein 90 inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | CA1 4406/4885CA2 4190/4885HSP90AA1 3/4885 |
| US-20190031620-A1 | NOVEL COMPOUND HAVING HSP90 INHIBITORY ACTIVITY OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND MEDICAL USE THEREOF | HSP90AA1, HSP90AB1, HSP90AB2P | CA1 4508/4885CA2 3493/4885HSP90AA1 1/4885 |
| US-20070197787-A1 | Heat shock protein 90 inhibitors | HSP90AB2P, HSP90AB1, HSP90AA1 | CA1 4406/4885CA2 4190/4885HSP90AA1 3/4885 |
| US-10464907-B2 | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof | HSP90AA1, HSP90AB1, HSP90AB2P | CA1 4519/4885CA2 3264/4885HSP90AA1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.